Time to DMARD (Disease-Modifying Anti-Rheumatic Drug) Treatment and Actual Work Limitation of Patients With Rheumatoid Arthritis in Turkey

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

356 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-02-28

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective is to measure time delay from onset of symptoms to diagnosis and time to disease-modifying anti-rheumatic drug treatments in Turkish patients with rheumatoid arthritis. The investigators will also evaluate actual work limitation status of patients and impact of demographic and clinical factors on work limitations in rheumatoid arthritis patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This post marketing observational study will be conducted in cross-sectional, non-interventional, multi-center format in Turkey. As this is a post marketing observational study, Abbott is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.

Subjects will be recruited from rheumatology outpatient clinics of university hospitals and/or private offices.

Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data will be included.

Patient data will be collected with a single visit. During the single visit, all required demographic and clinical data will be recorded on the case report forms by the investigators and every subject will be asked to fill out the Work Productivity and Activity Impairment questionnaire and the Health Assessment Questionnaire - Disability Index.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Work Limitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Turkish patients with rheumatoid arthritis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with rheumatoid arthritis by a specialist or by the treating rheumatologist
* Treated with at least one disease-modifying anti-rheumatic drug or biologics
* Patients over 18 years
* Patients already employed at a paid work
* Patients able to provide data for disease history
* Able to provide written consent to release information for this study

Exclusion Criteria

* Patients who cannot provide necessary outcome measurements for any reason will be excluded from the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mahmut Gucuk, MD

Role: STUDY_DIRECTOR

Abbott

Izmir, , Turkey (Türkiye)

Site Status

Site Ref # / Investigator 59226

Izmir, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P12-087

Identifier Type: -

Identifier Source: org_study_id

Time to DMARD (Disease-Modifying Anti-Rheumatic Drug) Treatment and Actual Work Limitation of Patients With Rheumatoid Arthritis in Turkey

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

Turkish patients with rheumatoid arthritis

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Abbott

Responsible Party

Principal Investigators

Mahmut Gucuk, MD

Locations

Site Reference ID/Investigator# 39111

Site Reference ID/Investigator# 39102

Site Reference ID/Investigator# 39104

Site Reference ID/Investigator# 39109

Site Reference ID/Investigator# 52448

Site Ref # / Investigator 52451

Site Reference ID/Investigator# 52442

Site Reference ID/Investigator# 52447

Site Reference ID/Investigator# 52446

Site Ref # / Investigator 52443

Site Reference ID/Investigator# 52444

Site Reference ID/Investigator# 52449

Site Reference ID/Investigator# 52450

Site Reference ID/Investigator# 39107

Site Reference ID/Investigator# 39106

Site Reference ID/Investigator# 39103

Site Reference ID/Investigator# 39108

Site Reference ID/Investigator# 36442

Site # / Investigator 59224

Site Ref # / Investigator 59225

Site Ref # / Investigator 59226

Countries

Other Identifiers

P12-087